The Highest Proportion of Surveyed MCOs Select Altace and Diovan as the Safest, Most Tolerable and Most Conveniently Deliv

One-Third of Surveyed Payers Identify Altace as the Most Efficacious Therapy for Diabetic Nephropathy, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest proportion of surveyed managed care organizations' (MCO) pharmacy directors select King Pharmaceuticals’ Altace and Novartis’s Diovan as the safest, most tolerable and most conveniently delivered agents for the treatment of diabetic nephropathy. The highest proportion of surveyed pharmacy directors select Altace as the most efficacious for the indication, while Diovan is viewed as having the best overall clinical profile when compared to other available therapies.

The DecisionBase 2011 report entitled Diabetic Nephropathy: High Unmet Need for Agents That Can Slow Progression to End-Stage Renal Disease Will Create Market Opportunities for Bardoxolone finds that approximately one-third of surveyed payers identify Altace as the most efficacious therapy for diabetic nephropathy. Payer opinion of Altace’s efficacy profile may be driven by its long-standing clinical record and widespread use. Payer opinions regarding which current therapies they consider to be the most efficacious are more evenly distributed than are the opinions of physicians, according to the report.

“While 35 percent of payers identified Altace as the most efficacious therapy, 15 percent selected Diovan as being the most efficacious,” said Decision Resources Analyst Henry Morgan Stewart. “In reality, payers may consider ACE inhibitors such as Altace and AIIRAs (angiotensin II receptor antagonists) such as Diovan to offer comparable efficacy, but they are biased in regard to Altace because it is much less expensive and thus offers a superior cost-benefit ratio.”

The findings also reveal that, based on clinical data and the opinions of interviewed thought leaders, Novartis’s Tekturna/Rasilez is the current gold-standard therapy for the treatment of diabetic nephropathy, owing to its strongest clinical profile among key marketed agents for the indication. However, owing to its advantages in efficacy and safety and tolerability, Abbott/Kyowa Hakko Kirin/Reata Pharmaceuticals' bardoxolone will displace Tekturna/Rasilez and will earn Decision Resources’ proprietary clinical gold-standard status for diabetic nephropathy in 2014, following its launch for the indication in 2014.

Webinar

Media members are welcome to attend our upcoming webinar entitled Unmet Needs in Diabetic Nephropathy: Dissatisfaction with the Current Standard of Care Equals Market Opportunities for Emerging Therapies. This webinar will be held on January 27 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at [email protected].

About DecisionBase 2011

DecisionBase 2011 combines clinical end points, market dynamics, reimbursement factors and primary research involving prescribers and payers to identify and quantify unmet need in 35 indications. As part of the unmet need analysis, patient share and sales are projected for key emerging drugs in development and for potential target product profiles based on physicians’ expectations.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.